The unintended consequences of Trump's copper tariff
The challenge for the US is that it has copper in the ground but its smelting and refining capacity has shrunk over the past several decades.
A slump in the copper price in the 1980s and 1990s led to the closure of US mines and smelters. In the late 1990s it still had 11 smelters in operation; today it has two, with a third that processes scrap.
By contrast, China, which saw a strategic opportunity in the 1990s, made major investments in smelting and now has more than half the world's smelting capacity. Ore from the rest of the world is exported to China to be smelted and refined and then either increasingly consumed within China – which is leading the global electrification race – or re-exported.
Given the centrality of copper to the 21st Century economy and advanced industrial and military technologies, China's dominance of the sector is obviously seen by the US as a national security threat.
The obvious response would be to produce and process more of its own copper. The problem it has is that most of its undeveloped resources are on federal land, which creates challenging and very lengthy approval processes. The average time to bring a new US mine into operation has blown out to about 29 years.
The giant Resolution copper project in Arizona owned by Rio Tinto and BHP, for instance, was discovered in 1995.
Rio submitted a mine plan for the project, in which the companies have already invested several billion dollars, in 2013. It took until May this year for the US Supreme Court to clear the way for a land swap, opposed by native Americans, that will enable the project to proceed. It will take a decade or more to actually bring a mine into production.
(BHP and Rio, via the giant Escondida mine in Chile will, incidentally, be exposed to the copper tariff, although more of that project's output is exported to Asia. Rio does have a mine – and a smelter – in the US that might benefit from the tariff and the higher domestic copper prices it will produce).
Adding more domestic supply of copper might address the threat of supply shortages and the increasing reliance on Latin America (although the US has a free trade agreements with Chile, the major producer), but it doesn't solve the shortage of processing capacity.
Loading
Smelters take at least a decade and $US3 billion-plus of investment to construct and involve environmentally unfriendly processes, which is part of the explanation for why much of the global capacity migrated to China which, at the time, was more interested in economic and strategic benefits than its environment.
Even if that capacity could be built in the US, it is unlikely to be competitive with China's smelters. China already has about 8 of the 20 largest copper smelters in the world.
In the meantime, with the likelihood that Trump's new tariff will apply not only to imports of refined copper but downstream semi-fabricated products like copper sheeting and wire, US manufacturers reliant on copper will face a steep increase in costs.
America's reliance on imported copper, once the tariff is in place, means that those manufacturers will not only incur higher costs that they will try to pass onto their own customers, but those costs will be unique to the US and therefore they will, to the extent that they compete outside the US or with imports, be at a significant competitive disadvantage.
The ubiquity of copper usage means that will be an economy-wide issue, adding to inflation while damaging US competitiveness. That's a familiar aspect of Trump's trade war on the rest of the world.
US copper buyers have already seen a preview of what's to come within the differential in US copper prices and those in the rest of the world as traders scrambled to get in ahead of the tariffs.
That rush to get their hands on physical metal not only forced the copper price to record levels, but has inverted the normal futures price curve for copper, known as contango, where future prices are higher than the spot price to reflect the costs of storage, opportunity costs and risk.
The price curve is now in 'backwardation' – spot prices are higher than future prices, with the prospect of losses for traders and hedged sellers of copper as their contracts expire and they are forced to cover their exposures at higher prices.
The shortage of physical metal in the market, driven by the urgency of getting ahead of the tariff, could lead to even more price rises and market disruption as sellers that have to deliver physical copper try to cover their positions.
Trump has claimed that 'trade wars are good and easy to win.' With copper, as with all of his other tariffs, he'll discover that they are nowhere near as straightforward as he has assumed, with hosts of unexpected and unintended consequences, some of them unpleasant and peculiarly so, not just for copper buyers and traders, but for US manufacturers and their customers.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


7NEWS
an hour ago
- 7NEWS
Donald Trump threatens 200 per cent tariff on pharmaceuticals, 50 per cent on copper, hitting Rio Tinto, BHP
Australia's mining giants BHP and Rio Tinto are set to be affected by a new 50 per cent tariff on copper imports announced by US President Donald Trump, as part of a broader push to boost American manufacturing. The tariff, which could take effect as early as this month or on August 1, comes as copper prices surged to record highs in the US following Mr Trump's comments. Mr Trump has indicated a potential 200 per cent tariff on pharmaceuticals, which are among Australia's largest exports to the US. However, he said manufacturers would be given time to relocate production to America to avoid the tariff. The US president also mentioned that copper could face a 50 per cent tariff. While Australia sends little copper directly to the US (less than one per cent of its total copper exports) both companies could see a small but direct impact from their global operations, including the Escondida mine in Chile. Until now, both pharmaceuticals and copper have been exempt from the US's shifting tariff policies, pending two separate investigations by the Department of Commerce. Mr Trump has frequently criticised America's reliance on foreign producers for these products, highlighting the critical role of imported medicines for health and copper for industry and technological progress. Speaking to reporters before a cabinet meeting, Mr Trump said drug manufacturers would receive a grace period to move their operations to the US. 'We're going to give (drug manufacturers) about a year, a year and a half to come in, and after that, they're going to be tariffed,' he said. 'They're going to be tariffed at a very, very high rate, like 200 per cent. We'll give them a certain period of time to get their act together.' Mt Trump also announced he will reveal at least seven more countries targeted for new trade measures on Wednesday US time, with additional nations to be named later in the day. The move comes following a wave of tariff threats against 14 countries earlier this week, including Japan and South Korea. In a post on Truth Social, Mr Trump said: 'We will be releasing a minimum of 7 countries having to do with trade, tomorrow morning, with an additional number of countries being released in the afternoon.' The White House recently extended the deadline for higher tariffs to August 1, giving countries a final window to negotiate deals or face new duties of up to 40 percent.

Sydney Morning Herald
2 hours ago
- Sydney Morning Herald
Trump flags tariff on foreign pharmaceuticals, but is he believable?
The threat by US President Donald Trump to impose a 200 per cent tariff on pharmaceutical imports would not only be a $2.2 billion blow to Australia but builds on the distrust, confusion and bewilderment around his scatter-gun and shifting policies. Trump has announced that foreign pharmaceutical producers would be given a grace period to move production to the US. 'We're going to give [drug manufacturers] about a year, a year and a half to come in, and after that, they're going to be tariffed,' he said. 'They're going to be tariffed at a very, very high rate, like 200 per cent.' With pharmaceutical products the third-biggest category in Australia's lopsided export trade with the US, after beef and gold, Trump's announcement unfortunately carries the taint of behind-the-scenes pressure from America's pharmaceutical industry. So-called 'Big Pharma' has an intense dislike of our Pharmaceutical Benefits Scheme, which forces drug companies to negotiate prices with the Australian government rather than individual buyers. The scheme gives purchasing power to the government, keeps prices down and infuriates grasping US drug industry leaders. They have lobbied the Trump administration to impose retaliatory tariffs on Australia. Treasurer Jim Chalmers gave short shrift to Trump's latest tariff gambit and ruled out changes to the PBS. 'I want to make it really clear, once again, as we have on a number of occasions before, our Pharmaceutical Benefits Scheme is not something that we're willing to trade away or do deals on,' Chalmers told ABC Radio. The week Trump announced his tariffs, the Herald reported on Michael Smith, a former meat worker from Leeton, who has been given the first next-generation device that mimics the heart's pulse to help pump blood around the body. Doctors at Sydney's St Vincent's Hospital described it as a quantum leap in the technology that has saved thousands of lives from heart failure. Many people in charge in the US are as antagonistic to such government-subsidised research as they are to the PBS, yet simultaneously remain steadfastly oblivious to the rottenness of their health system. Loading Trump has been talking about pharmaceuticals since he began rolling out his tariff agenda, despite industry concerns that duties could wreak havoc on supply chains, exacerbate drug shortages and drive up costs for everyday Americans who are already shackled by an expensive health system that is not universal and primarily serves the wealthy or the employed, whose employers pay their health insurance. The term TACO trade – Trump Always Chickens Out – was coined by an English commentator in May to describe the president's pattern of announcing heavy tariffs on countries, causing economic shock, panic and stock market hits, and then reversing course with pauses or reductions that create a market rebound. The world has taken Trump's latest tariff threats with a grain of salt, with global share markets barely budging.

Sky News AU
2 hours ago
- Sky News AU
‘Playing with fire': Warning over US President Donald Trump's 50 per cent copper tariffs as Labor struggles to negotiate
Pain for consumers could be on the cards after Donald Trump revealed massive tariffs and Labor struggles to negotiate any exemptions. President Trump this week vowed to enforce 50 per cent tariffs on copper and US commerce secretary Howard Lutnick said the levies would come into effect from July or August 1. It comes as the Albanese government struggles to negotiate tariff exemptions with Trump. Two allies — United Kingdom and Canada — have already secured exemptions amid broader negotiations and commitments to significantly lift defence spending. However, Mr Albanese has been unable to even meet President Trump face to face, much less negotiate a trade deal. Copper prices have soared on Wednesday following Trump's announcement with the metal up more than 14 per cent compared to Tuesday. Commonwealth Bank of Australia's commodities specialist Vivek Dhar warned of pain across the global economy amid the price hikes. 'It may benefit upstream in terms of (US) copper producers, but if you go further downstream to those that consume copper, the higher price paid is something that can really hurt that industry,' Mr Dhar said on Business Now. 'This is something we have precedence of. If we go back to 2018 to 2021, this is exactly what happened with steel and aluminium.' He warned the Trump Administration could ultimately hurt the US economy if its tariff plan goes awry. 'I think the US is really playing with fire and if it doesn't go to plan it could actually be worse for the US economy, just given how the downstream sector response," Mr Dhar said. Multinationals BHP and Rio Tinto have come under the microscope since Trump revealed the massive levies. Both companies mine copper in South America, while BHP also mines in South Australia and Rio Tinto mines in Mongolia. Further backlash to Trump's copper tariff came from Minerals Council of Australia CEO Tania Constable, who said the measures would 'disrupt global trade, undermine investment confidence, and increase costs for consumers including in the United States'. 'Sudden and sweeping trade actions only heighten uncertainty and constrain the ability of businesses to plan, invest and grow,' Ms Constable said. 'The right response is not to raise barriers, but to make economies more resilient, productive and globally connected. 'While Australia's direct copper exports to the United States are limited, trade restrictions imposed on other key trading partners have the potential of disrupting global supply chains, increasing costs, and creating uncertainty for Australian exporters.' Trump's announcement rattled many companies on the ASX including Capstone Copper (down 3.3 per cent), Sandfire Resources (down 3.4 per cent) and Evolution Mining (down 6.6 per cent). The copper levies come alongside planned 200 per cent tariffs on pharmaceuticals that Trump said his administration will enforce in about 'a year (or a) year and a half'. 'We'll give them a certain period of time to get their act together,' Trump said about drugmakers bringing manufacturing to the U.S. Treasurer Jim Chalmers remains on alert after Trump revealed the swath of levies. 'These are obviously very concerning developments,' he told ABC RN. 'It's been a feature of recent months that we've had these sorts of announcements out of DC. 'It's still early days. Obviously, we'll make a more detailed assessment of what's come out of the US in the usual way. The two big announcements were obviously regarding copper and pharmaceuticals.'